

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



華潤醫藥集團有限公司

China Resources Pharmaceutical Group Limited

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3320)

POLL RESULTS OF ANNUAL GENERAL MEETING HELD ON 12 JUNE 2026

References are made to (i) the circular of China Resources Pharmaceutical Group Limited (the “**Company**”) dated 19 May 2026 (the “**Circular**”); and (ii) the notice of Annual General Meeting dated 19 May 2026 (the “**Notice of Annual General Meeting**”). Unless otherwise defined, capitalised terms used herein shall have the same meanings as those defined in the Circular.

The Company is pleased to announce the poll results in respect of the resolutions proposed at the Annual General Meeting held on 12 June 2026 as follows:

Ordinary Resolutions proposed at the Annual General Meeting			Number of Votes (%)	
			For	Against
1.	To receive and consider the audited financial statements, the directors’ report and the independent auditor’s report of the Company for the year ended 31 December 2025.		4,932,351,938 (99.79%)	10,257,813 (0.21%)
The resolution was duly passed as an ordinary resolution.				
2.	To declare a final dividend of RMB0.122 per share for the year ended 31 December 2025.		4,942,588,750 (99.99%)	21,000 (0.01%)
The resolution was duly passed as an ordinary resolution.				
3.	(1)	To re-elect Mr. Bai Xiaosong as an executive Director.	4,672,668,504 (94.66%)	263,723,246 (5.34%)
The resolution was duly passed as an ordinary resolution.				
	(2)	To re-elect Mr. Cheng Jie as an executive Director.	4,911,769,465 (99.38%)	30,840,285 (0.62%)
The resolution was duly passed as an ordinary resolution.				
	(3)	To re-elect Mr. Liu Changan as an executive Director.	4,917,461,623 (99.49%)	25,148,127 (0.51%)
The resolution was duly passed as an ordinary resolution.				

Ordinary Resolutions proposed at the Annual General Meeting			Number of Votes (%)	
			For	Against
	(4)	To re-elect Mr. Sun Yongqiang as a non-executive Director.	4,907,370,843 (99.29%)	35,238,907 (0.71%)
The resolution was duly passed as an ordinary resolution.				
	(5)	To re-elect Mr. Wang Yuhang as a non-executive Director.	4,915,996,623 (99.46%)	26,613,127 (0.54%)
The resolution was duly passed as an ordinary resolution.				
	(6)	To re-elect Mdm. Jiao Ruifang as a non-executive Director.	4,865,057,882 (98.43%)	77,551,868 (1.57%)
The resolution was duly passed as an ordinary resolution.				
	(7)	To re-elect Mr. Shi Luwen as an independent non-executive Director.	4,794,375,037 (97.12%)	142,016,713 (2.88%)
The resolution was duly passed as an ordinary resolution.				
4.		To authorise the Board to fix the remuneration of the Directors	4,938,818,162 (99.92%)	3,791,588 (0.08%)
The resolution was duly passed as an ordinary resolution.				
5.		To appoint KPMG as the auditor of the Company and to authorise the Board to fix their remuneration.	4,941,961,250 (99.99%)	648,500 (0.01%)
The resolution was duly passed as an ordinary resolution.				
6.		To give a general mandate to the Directors to buy back shares of the Company. (Ordinary Resolution in item No.6 of the Notice of Annual General Meeting)	4,941,517,510 (99.98%)	1,092,240 (0.02%)
The resolution was duly passed as an ordinary resolution.				
7.		To give a general mandate to the Directors to issue new shares of the Company. (Ordinary Resolution in item No.7 of the Notice of Annual General Meeting)	4,541,361,533 (92.00%)	395,030,217 (8.00%)
The resolution was duly passed as an ordinary resolution.				
8.		To extend the general mandate to be given to the Directors to issue new shares of the Company. (Ordinary Resolution in item No.8 of the Notice of Annual General Meeting)	4,543,381,701 (92.04%)	393,010,049 (7.96%)
The resolution was duly passed as an ordinary resolution.				

As at the date of the Annual General Meeting, the total number of issued and fully paid-up Shares was 6,282,510,461 Shares. In relation to all resolutions proposed at the Annual General Meeting, the total number of Shares entitling the holders to attend and vote for or against the resolutions at the Annual General Meeting was 6,282,510,461 Shares. As at the date of the Annual General Meeting, the Company did not hold any treasury shares (including any treasury shares held or deposited with CCASS), and no repurchased Shares which are pending cancellation and should be excluded from the total number of issued Shares for the purpose of the Annual General Meeting. There were no Shares entitling the holders to attend and abstain from voting in favour of the resolutions at the Annual General Meeting as set out in Rule 13.40 of the Listing Rules and there were no Shares requiring the holders to abstain from voting at the Annual General Meeting under the Listing Rules. No Shareholders have stated their intention in the Circular to vote against or to abstain from voting on any of the proposed resolutions at the Annual General Meeting.

Mr. Liu Changan, an executive Director of the Company, presided the Annual General Meeting. The Directors Mdm. Guo Wei, Mr. Sun Yongqiang, Mr. Wang Yuhang, Mr. Guo Chuan, Mdm. Jiao Ruifang, Mdm. Chiu Mum Wai, Mr. Fu Tingmei and Mr. Shi Luwen attended the Annual General Meeting in person or via video conference, whilst Mr. Bai Xiaosong, Mr. Cheng Jie and Mr. Zhang Kejian were unable to attend the Annual General Meeting due to other business commitments.

Tricor Investor Services Limited, the share registrar of the Company, acted as scrutineers for the vote-taking at the Annual General Meeting.

Shareholders may refer to the Circular for details of the above resolutions proposed at the Annual General Meeting. The Circular may be viewed and downloaded from the Company's website at www.crpharm.com or the website of the Stock Exchange at www.hkexnews.hk.

For and on behalf of
China Resources Pharmaceutical Group Limited
Bai Xiaosong
Chairman

PRC, 12 June 2026

As at the date of this announcement, the Board comprises Mr. Bai Xiaosong as chairman and executive Director; Mr. Cheng Jie and Mr. Liu Changan as executive Directors; Mdm. Guo Wei, Mr. Sun Yongqiang, Mr. Wang Yuhang, Mr. Guo Chuan and Mdm. Jiao Ruifang as non-executive Directors and Mdm. Chiu Mun Wai, Mr. Fu Tingmei, Mr. Zhang Kejian and Mr. Shi Luwen as independent non-executive Directors.